600332.SHG Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
- Market cap
- CNY 32.8B
- P/E
- 15.2x
- P/B
- 0.84x
- ROE
- 8.5%
- Dividend yield
- 3.97%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600332.SHG undervalued?
Graham number600332.SHG trades 24.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd fundamental analysis
No fundamental analysis for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd yet.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, development, manufacturing, and sale of chemical drugs, chemical raw materials, and ch…
Full company profileGuangzhou Baiyunshan Pharmaceutical Holdings Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 20.0B | 21.0B | 42.2B | 65.0B | 61.7B | 69.0B | 70.8B | 75.5B | 75.0B | 77.4B | 82.8B |
| Gross Profit | 6.60B | 7.88B | 10.00B | 12.2B | 10.4B | 13.2B | 13.2B | 14.1B | 12.5B | 11.8B | 13.5B |
| Operating Income | 1.47B | 2.46B | 3.84B | 4.06B | 3.67B | 4.79B | 5.07B | 5.12B | 3.60B | 3.10B | 4.50B |
| EBITDA | 1.40B | 2.16B | 2.68B | 3.90B | 3.42B | 4.39B | 5.00B | 5.46B | 4.07B | 4.06B | 4.67B |
| Net Income | 1.51B | 2.06B | 3.44B | 3.19B | 2.92B | 3.72B | 3.97B | 4.06B | 2.84B | 2.98B | 3.32B |
| EPS | 1.08 | 1.27 | 2.12 | 1.96 | 1.79 | 2.29 | 2.44 | 2.49 | 1.74 | 1.83 | 2.04 |
| Balance Sheet | |||||||||||
| Total Assets | 25.9B | 28.3B | 51.5B | 56.9B | 59.8B | 66.1B | 74.7B | 78.6B | 81.7B | 84.5B | 87.2B |
| Total Liabilities | 8.24B | 9.05B | 28.3B | 30.9B | 31.6B | 34.8B | 41.0B | 41.9B | 43.9B | 43.4B | 45.8B |
| Shareholders' Equity | 17.3B | 18.9B | 21.7B | 24.2B | 26.1B | 29.1B | 32.1B | 34.9B | 35.9B | 37.8B | 39.0B |
| Cash & Short-term Investments | 13.1B | 11.7B | 16.1B | 18.5B | 19.5B | 22.4B | 22.6B | 22.0B | 22.7B | 23.8B | 11.9B |
| Total Debt | 58.7M | 42.8M | 6.52B | 6.65B | 9.56B | 9.92B | 11.4B | 11.7B | 12.4B | 20.7B | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.44B | 1.83B | 5.22B | 5.02B | 585M | 5.67B | 7.00B | 4.10B | 3.44B | 260M | - |
| Capital Expenditure | 228M | 197M | 479M | 2.40B | 877M | 1.25B | 1.38B | 1.63B | 1.13B | 1.24B | 1.01B |
| Free Cash Flow | 2.22B | 1.64B | 4.74B | 2.62B | -291M | 4.42B | 5.62B | 2.48B | 2.31B | -980M | -715M |
| Ratios | |||||||||||
| ROE | 8.7% | 10.9% | 15.9% | 13.2% | 11.2% | 12.8% | 12.4% | 11.6% | 7.9% | 7.9% | 8.5% |
| ROA | 5.8% | 7.3% | 6.7% | 5.6% | 4.9% | 5.6% | 5.3% | 5.2% | 3.5% | 3.5% | 3.8% |
| Net Profit Margin | 7.5% | 9.8% | 8.1% | 4.9% | 4.7% | 5.4% | 5.6% | 5.4% | 3.8% | 3.9% | 4.0% |
| Debt to Equity | 0.00x | 0.00x | 0.30x | 0.27x | 0.37x | 0.34x | 0.36x | 0.34x | 0.34x | 0.55x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd dividends
- Dividend yield
- 3.97%
- Forward dividend
- 0.75 CNY
- Payout ratio
- 43.6%
- Ex-dividend date
- Sep 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.30B | 0.80 | 43.6% |
| 2024 | CNY 2.25B | 1.38 | 79.4% |
| 2023 | CNY 1.19B | 0.73 | 29.3% |
| 2022 | CNY 1.12B | 0.69 | 28.2% |
| 2021 | CNY 875M | 0.54 | 23.5% |
| 2020 | CNY 958M | 0.59 | 32.8% |
| 2019 | CNY 689M | 0.42 | 21.6% |
| 2018 | CNY 871M | 0.54 | 25.3% |
| 2017 | CNY 464M | 0.29 | 22.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
- Insiders 58.65%
- Institutions 3.09%
- Public & others 38.26%
- Shares outstanding 1.41B
- Free float 873M
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd company profile
- Company name
- Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
- Ticker
- 600332.SHG
- ISIN
- CNE000001733
- Exchange
- Shanghai Stock Exchange
- Listed since
- Oct 30, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 27,057
- Fiscal year end
- December
- Address
- No. 45, Sha Mian North Street, Guangzhou, China, 510130
- Phone
- 86 20 6628 1011
- Website
- gybys.com.cn
About Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, development, manufacturing, and sale of chemical drugs, chemical raw materials, and chemical raw material intermediates; and research, development, production, and sale of health products; and wholesale, retail, and import export of Western medicines, traditional Chinese medicines, and medical devices. The company also offers bio-innovation, consumer health, and medical services; Xiaochaihu granules; Qingkailing and Baoji, Xia Sangju product series; Angong Niuhuang, Zishen Yutai, Xiaoke, Huatuo Zaizao, Zhuangyao Jianshen, and Shujin Jianyao pills; compound Danshen and Naoxinqing tablet series; Banlangen, Compound Banlangen, and Dashen Kouyanqing granules series; and honey-processed Chuanbei and Shedan Chuanbei loquat syrup. In addition, it provides antibacterial and anti-inflammatory drugs, andrological drugs, and analgesics and antipyretics; Wanglaoji herbal tea, Ciningji series, Lixiaoji series, and Yerou coconut milk; and advertising services. Further, the company engages in the medical research industry; technology services industry; leasing and business services; and scientific research and technical services industry. It operates through hospitals, community healthcare facilities, and retail outlets through distributors and agents. The company was formerly known as Guangzhou Pharmaceutical Company Limited and changed its name to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited in August 2013. Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited was incorporated in 1997 and is based in Guangzhou, China.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd management
8- Mr. Jiehui ChenExecutive Chairman · born 1976
- Ms. Liu FeiChief Financial Officer · born 1977
- Ms. Haoshan ZhengDeputy GM & Director of Business Administration Department · born 1975
- Mr. Hongjin ChengExecutive Director
- Mr. Heping TangExecutive Director
- Ms. Xuezhen HuangSecretary · born 1975
- Mr. Cheng YuanGM & Executive Deputy Chairman
- Ms. Lan LiuExecutive Director · born 1978